Top-Rated StocksTop-RatedNASDAQ:ITCI Intra-Cellular Therapies (ITCI) News Today $61.32 +1.79 (+3.01%) (As of 06/2/2023 ET) Add Compare Share Share Today's Range$59.03▼$61.6650-Day Range$47.88▼$66.4452-Week Range$42.01▼$66.56Volume661,392 shsAverage Volume630,174 shsMarket Capitalization$5.88 billionP/E RatioN/ADividend YieldN/APrice Target$74.45 HeadlinesProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Get Intra-Cellular Therapies News Delivered to You Automatically Sign up to receive the latest news and ratings for ITCI and its competitors with MarketBeat's FREE daily newsletter. Email Address ITCI Media Mentions By Week ITCI Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ITCI News Sentiment▼0.580.56▲Average Medical News Sentiment ITCI News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ITCI Articles This Week▼43▲ITCI Articles Average Week All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineSei Investments Co. Reduces Stake in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)marketbeat.com - June 4 at 6:19 AMIntra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Acquired by Connor Clark & Lunn Investment Management Ltd.marketbeat.com - June 1 at 6:51 AMIntra-Cellular Therapies Announces CAPLYTA Data Presentations at the American Society of Clinical Psychopharmacology Annual Meetingfinance.yahoo.com - May 31 at 8:26 AMIntra-Cellular Therapies Announces CAPLYTA Data Presentations at the American Society of Clinical Psychopharmacology Annual Meetingfinance.yahoo.com - May 31 at 8:26 AMBrokerages Set Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Target Price at $74.45americanbankingnews.com - May 28 at 3:14 AMFranklin Resources Inc. Cuts Stake in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)marketbeat.com - May 26 at 7:58 AMIntra-Cellular Therapies, Inc. (NASDAQ:ITCI) Given Average Recommendation of "Moderate Buy" by Brokeragesmarketbeat.com - May 25 at 3:16 AMLord Abbett & CO. LLC Sells 1,131,313 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)marketbeat.com - May 19 at 12:19 PMEnvestnet Asset Management Inc. Sells 2,080 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)marketbeat.com - May 17 at 4:56 AMHead to Head Analysis: Intra-Cellular Therapies (NASDAQ:ITCI) and Arbutus Biopharma (NASDAQ:ABUS)americanbankingnews.com - May 17 at 2:58 AMCalifornia Public Employees Retirement System Trims Stock Holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)marketbeat.com - May 16 at 5:14 AMMizuho Maintains Intra-Cellular Therapies (ITCI) Buy Recommendationmsn.com - May 8 at 8:50 PMInvesting in Intra-Cellular Therapies (NASDAQ:ITCI) three years ago would have delivered you a 208% gainfinance.yahoo.com - May 8 at 10:46 AMIntra-Cellular Therapies (NASDAQ:ITCI) Price Target Raised to $76.00americanbankingnews.com - May 8 at 7:38 AMCantor Fitzgerald Raises Intra-Cellular Therapies (NASDAQ:ITCI) Price Target to $90.00americanbankingnews.com - May 8 at 4:50 AMCantor Fitzgerald Maintains Intra-Cellular Therapies (ITCI) Overweight Recommendationmsn.com - May 5 at 11:52 PMRBC Capital Maintains Intra-Cellular Therapies (ITCI) Outperform Recommendationmsn.com - May 5 at 11:52 PMCantor Fitzgerald Boosts Intra-Cellular Therapies (NASDAQ:ITCI) Price Target to $90.00marketbeat.com - May 5 at 11:55 AMIntra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Sold by Duality Advisers LPmarketbeat.com - May 5 at 7:04 AM‘Don’t let the earnings beats fool you’: Morgan Stanley advises investors to temper their optimism amidst a looming recession — use these 2 stocks for protectionfinance.yahoo.com - May 4 at 10:49 PMIntra-Cellular Therapies Inc.: Intra-Cellular Therapies Reports First Quarter 2023 Financial Results and Provides Corporate Updatefinanznachrichten.de - May 4 at 12:47 PMRecap: Intra-Cellular Therapies Q1 Earningsmsn.com - May 4 at 12:47 PMIntra-Cellular Therapies Q1 2023 Earnings Previewmsn.com - May 4 at 7:47 AMIntra-Cellular Therapies Reports First Quarter 2023 Financial Results and Provides Corporate Updatefinance.yahoo.com - May 4 at 7:47 AMIntra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Bought by Los Angeles Capital Management LLCmarketbeat.com - May 4 at 5:27 AMIntra-Cellular Therapies, Inc. (NASDAQ:ITCI) Receives $74.00 Average Price Target from Analystsamericanbankingnews.com - May 3 at 2:52 AMIntra-Cellular Therapies, Inc. (NASDAQ:ITCI) Given Average Rating of "Moderate Buy" by Analystsmarketbeat.com - April 30 at 2:46 AMBanque Pictet & Cie SA Grows Stake in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)marketbeat.com - April 28 at 6:44 AMIntra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Purchased by SG Americas Securities LLCmarketbeat.com - April 27 at 5:29 AMIntra-Cellular Therapies to Host First Quarter 2023 Financial Results Conference Call and Webcastfinance.yahoo.com - April 26 at 10:13 AMAE Wealth Management LLC Buys New Shares in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)marketbeat.com - April 26 at 4:31 AMSVB Leerink Comments on Intra-Cellular Therapies, Inc.'s FY2027 Earnings (NASDAQ:ITCI)americanbankingnews.com - April 25 at 3:20 AMIntra-Cellular Therapies, Inc. (NASDAQ:ITCI) to Post FY2027 Earnings of $6.05 Per Share, SVB Leerink Forecastsmarketbeat.com - April 24 at 3:24 AMOLD National Bancorp IN Sells 19,874 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)marketbeat.com - April 23 at 7:18 AMMorgan Stanley Begins Coverage on Intra-Cellular Therapies (NASDAQ:ITCI)americanbankingnews.com - April 22 at 6:36 AMIntra-Cellular Therapies, Inc. (NASDAQ:ITCI) Director Sells $630,000.00 in Stockamericanbankingnews.com - April 22 at 4:38 AMMorgan Stanley Reiterates Intra-Cellular Therapies (ITCI) Overweight Recommendationmsn.com - April 21 at 12:35 PM11,031 Shares in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Acquired by Mach 1 Financial Group LLCmarketbeat.com - April 21 at 8:54 AMMorgan Stanley starts Intra-Cellular at Overweight on schizophrenia therapymsn.com - April 20 at 4:32 PMMorgan Stanley Initiates Coverage of Intra-Cellular Therapies (ITCI) with Overweight Recommendationmsn.com - April 20 at 4:32 PMIBD 50 Stocks To Watch: This Drug Stock Up 36% In Six Weeks After Positive Trial Newsfinance.yahoo.com - April 20 at 4:32 PMIntra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Sold by Bailard Inc.marketbeat.com - April 20 at 7:51 AMIntra-Cellular Therapies, Inc. (NASDAQ:ITCI) Short Interest Updateamericanbankingnews.com - April 20 at 2:44 AMNeedham Maintains Intra-Cellular Therapies (ITCI) Buy Recommendationmsn.com - April 19 at 5:43 PMAtonRa Partners Sells 2,568 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)marketbeat.com - April 18 at 12:25 PMShort Interest in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Grows By 27.6%marketbeat.com - April 18 at 2:39 AMVahanian & Associates Financial Planning Inc. Has $984,000 Stock Holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)marketbeat.com - April 14 at 10:42 AMIntra-Cellular Therapies to Present at the 22nd Annual Needham Virtual Healthcare Conferencefinance.yahoo.com - April 11 at 12:19 PMIntra-Cellular Therapies, Inc. (NASDAQ:ITCI) Receives $71.92 Average Price Target from Analystsamericanbankingnews.com - April 10 at 6:46 AMRBC Capital Sticks to Its Buy Rating for Intra-Cellular Therapies (ITCI)markets.businessinsider.com - April 8 at 7:13 AM Get Intra-Cellular Therapies News Delivered to You Automatically Sign up to receive the latest news and ratings for ITCI and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: IONS News GRFS News OGN News ISEE News CERE News ASND News MDGL News CTLT News ALKS News ROIV News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat Originals This page (NASDAQ:ITCI) was last updated on 6/4/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Intra-Cellular Therapies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.